← All insights
Week of October 5, 2026

October 2026 Funding: $2.6B in Healthcare AI Biotech Deals

Top Healthcare and Biotechnology Raises

Neko Health secured the week's largest round with a $700.0M venture round in healthcare, underscoring investor appetite for advanced medical technology platforms. Neko Health led activity in the sector. In biotechnology, LISATA THERAPEUTICS, INC. closed a $351.9M private placement, bolstering its clinical pipeline. LISATA THERAPEUTICS, INC. attracted strong interest from specialized life-sciences investors. Two other health care companies followed: Edgewood OpCo, LLC raised $87.0M and Click Therapeutics, Inc. raised $50.0M through private placements. Edgewood OpCo, LLC and Click Therapeutics, Inc. expanded the healthcare total beyond $1.2B.

AI and Technology Funding Highlights

EliseAI captured attention with a $350.0M venture round in artificial intelligence, one of the largest AI deals tracked this period. EliseAI demonstrates continued momentum for enterprise AI applications. Other technology companies contributed substantially: General Intuition Holding B.V. raised $175.2M, CScale, Inc. closed $145.0M, Quartermaster AI, Inc secured $122.6M, and Niobium Microsystems, Inc. obtained $50.0M, all via private placements. General Intuition Holding B.V., CScale, Inc., Quartermaster AI, Inc, and Niobium Microsystems, Inc. pushed the combined AI and other technology tally past $840M.

Additional Sector Activity

Mascoma Mutual Financial Services Corp completed a $35.0M private placement in commercial banking. Mascoma Mutual Financial Services Corp provided the only banking-sector transaction among the ten notable raises. Together the ten deals reached $2.6B, concentrated in healthcare, biotechnology, AI, and other technology.

Weekly Takeaway

These rounds highlight sustained institutional focus on clinically validated healthcare solutions and scalable AI infrastructure. Search interest for recently funded healthcare startups and biotechnology venture deals October 2026 is expected to rise as more investors review the October 5, 2026 pipeline.